Elevance Health Inc. (ELV) Misses Q2 EPS by 23c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Elevance (ELV) PT Lowered to $350 at BofA Securities
July 17, 2025 12:10 PM EDTBofA Securities analyst Kevin Fischbeck lowered the price target on Elevance (NYSE: ELV) to $350.00 (from $420.00) while maintaining a Neutral rating.
The analyst comments "Despite a Q2 in-line with company expectations, ELV cut guidance by 13%, citing higher trend in exchanges... More
